NDA 211340 · Azurity
Katerzia
Amlodipine Benzoate · Oral
Last checked: Nov 19, 2026Latest source record: Sep 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 8, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
272,620
210,866 serious, 29,868 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2025.
KATERZIA is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) KATERZIA is indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal’s or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%. 1.1 Hypertension KATERZIA is indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to...
Mechanism: Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- KATERZIA · AMLODIPINE BENZOATE EQ 1MG BASE/ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amlodipine Benzoate" as an intervention, any sponsor and status, largest first.
- Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia PatientsStatus unknown
Kevin H.M. Kuo, MD, MSc, FRCPCAcademic, hospital or other
NCT02474420 · 60 participants (planned) · Start Jun 2015 · Primary completion Jun 2017
Drug: Amlodipine; Deferasirox · For: Beta-Thalassemia; Iron Overload
Sites: Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue16,575
- diarrhoea14,880
- nausea14,108
- dyspnoea13,790
- drug ineffective12,841
- off label use12,062
- dizziness11,278
- headache10,422
- acute kidney injury9,953
- pain9,610
- vomiting9,272
- fall8,925
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 744 |
| 2005 | 878 |
| 2006 | 1,036 |
| 2007 | 1,407 |
| 2008 | 1,912 |
| 2009 | 3,213 |
| 2010 | 4,129 |
| 2011 | 5,415 |
| 2012 | 7,098 |
| 2013 | 7,601 |
| 2014 | 10,322 |
| 2015 | 14,615 |
| 2016 | 16,314 |
| 2017 | 18,466 |
| 2018 | 22,937 |
| 2019 | 24,686 |
| 2020 | 23,029 |
| 2021 | 20,669 |
| 2022 | 18,630 |
| 2023 | 19,083 |
| 2024 | 17,923 |
| 2025 | 18,338 |
| 2026 | 14,174 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Katerzia (Amlodipine Benzoate)
2024 spending
$1.5M
Beneficiaries
375
1,715 claims
Per beneficiary
$4,023
$3.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,029,566 |
| 2021 | $1,407,521 |
| 2022 | $1,392,621 |
| 2023 | $1,460,851 |
| 2024 | $1,508,546 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.